Regenerative Medical Technology Group Inc.
Other OTCTotal Valuation
Regenerative Medical Technology Group Inc. carries a market capitalization of 375,774.00, placing it among publicly traded companies globally. Its enterprise value stands at 19.87M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 375,774.00 |
| Enterprise Value | 19.87M |
Share Statistics
Regenerative Medical Technology Group Inc. currently has 13.14M shares outstanding.
| Shares Outstanding | 13.14M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.05, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.05 |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.01 |
| P/FCF Ratio | 1.37 |
| P/OCF Ratio | -0.53 |
Enterprise Valuation
On an enterprise value basis, Regenerative Medical Technology Group Inc. trades at an EV/EBITDA multiple of 43.57 and an EV/FCF ratio of 2.21. The EV/Sales ratio of 3.12 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 69.20 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.12 |
| EV / EBITDA | 43.57 |
| EV / EBIT | 69.20 |
| EV / FCF | 2.21 |
Financial Position
Regenerative Medical Technology Group Inc. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -57.77, indicating conservative leverage, while an interest coverage ratio of -0.05 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.04 |
| Quick Ratio | 0.03 |
| Debt / Equity | -57.77 |
| Debt / EBITDA | -46.20 |
| Interest Coverage | -0.05 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -176.38 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 17.08 |
Stock Price Statistics
Regenerative Medical Technology Group Inc.'s stock has declined approximately -18.28571% over the past 52 weeks. The 50-day moving average sits at 0.04, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.28571% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Regenerative Medical Technology Group Inc. generated 6.38M in revenue and converted that into -7.93M in net income, yielding earnings per share of -0.62. EBITDA reached -445,391.00, while operating income came in at -772,338.00.
| Revenue | 6.38M |
| Gross Profit | 3.63M |
| Operating Income | -772,338.00 |
| Pretax Income | -7.93M |
| Net Income | -7.93M |
| EBITDA | -445,391.00 |
| EBIT | -772,338.00 |
| Earnings Per Share (EPS) | -0.62 |
Balance Sheet
Regenerative Medical Technology Group Inc. holds 1.06M in cash and equivalents against 20.58M in total debt, resulting in a net debt position of 18.93M. Total book value stands at -76.23M, with working capital of -36.64M providing operational flexibility.
| Cash & Cash Equivalents | 1.06M |
| Total Debt | 20.58M |
| Net Debt | 18.93M |
| Equity (Book Value) | -76.23M |
| Book Value Per Share | -5.98 |
| Working Capital | -36.64M |
Cash Flow
Regenerative Medical Technology Group Inc. produced -661,504.00 in operating cash flow over the past twelve months. After subtracting -917,977.00 in capital expenditures, free cash flow totaled -1.58M - equivalent to -0.12 per share.
| Operating Cash Flow | -661,504.00 |
| Capital Expenditures | -917,977.00 |
| Free Cash Flow | -1.58M |
| FCF Per Share | -0.12 |
Margins
Regenerative Medical Technology Group Inc. operates with a gross margin of 56.99, reflecting its pricing power and cost economics. The operating margin of -12.11 and net profit margin of -124.36 provide insight into operational efficiency.
| Gross Margin | 56.99 |
| Operating Margin | -12.11 |
| Pretax Margin | -124.36 |
| Profit Margin | -124.36 |
| EBITDA Margin | -6.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -404.77 |
| FCF Yield | 73.21 |
Stock Splits
Regenerative Medical Technology Group Inc.'s most recent stock split took place on September 26, 2018 with a 1000:1 split ratio.
| Last Split Date | 9/26/2018 |
| Split Ratio | 1000:1 |
Scores
Regenerative Medical Technology Group Inc. posts an Altman Z-Score of -44.60, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -44.60 |